Breast cancer. Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: Intervention group: after obtaining informed consent and explaining the objectives of the research, aspirin 81 milligrams daily is given to the intervention group. Intervention 2: Con
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Women aged 18 to 70 with breast cancer who have been confirmed by histopathological diagnosis 2. Stage II to III who are candidates for neoadjuvant chemotherapy 3. Zero or on Eastern Cooperative Oncology Groupperformance index 4. Informed consent to enter the study
Exclusion criteria
Exclusion criteria: 1. Patients with a history of other malignancies, a history of myocardial infarction, a history of atrial fibrillation, and a history of grade hypertension 2. Contraindications of aspirin use 3. Simultaneous use of warfarin, heparin or heparin analogues, clopidogrel, thrombin inhibitors or coagulation factors 4. History of taking aspirin within 30 days before entering the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete pathologic response. Timepoint: 4 month. Method of measurement: Pathology report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRoghaye Abdollahi
Kerman University of Medical Sciences
Outcome results
None listed